Clinical Approach to Jaundice

Pediatric Comprehensive Framework

1
Symptom Overview
Overview
2
Pathophysiology
Mechanism
3
History Taking
History
4
Physical Examination
Examination
5
Differential Diagnosis
Differential
6
Investigations
Workup
7
Clinical Decision-Making
Algorithm
8
Pearls and Pitfalls
Summary

1. Symptom Overview

Understanding the clinical significance and classification of jaundice in pediatric patients

Jaundice is one of the most common clinical findings in newborns and a frequent reason for hospital readmission in the first week of life. Approximately 60% of term newborns and 80% of preterm newborns develop visible jaundice during the first week of life. While most neonatal jaundice is benign and self-limiting, severe hyperbilirubinemia can lead to acute bilirubin encephalopathy and kernicterus, making early recognition and appropriate management critical. Beyond the neonatal period, jaundice in children is less common but often signifies underlying hepatobiliary disease requiring prompt evaluation.

Definition

Jaundice (icterus) is the yellow discoloration of the skin, sclera, and mucous membranes resulting from elevated serum bilirubin levels. In neonates, jaundice becomes clinically visible when total serum bilirubin exceeds approximately 5 mg/dL (85 μmol/L). In older children, jaundice is typically visible at levels above 2-3 mg/dL (34-51 μmol/L). The yellow pigmentation progresses in a cephalocaudal direction, appearing first on the face and progressing to the trunk and extremities as bilirubin levels rise.

Key Epidemiology

60% of term newborns develop visible jaundice
80% of preterm newborns develop visible jaundice
2-3% of breastfed infants have prolonged jaundice beyond 2 weeks

Severe hyperbilirubinemia occurs in 1-2 per 10,000 live births
Biliary atresia incidence: 1 in 10,000-15,000 live births
Leading cause of hospital readmission in first week of life

Classification by Age of Onset

The timing of jaundice onset is one of the most critical factors in determining etiology and urgency of evaluation, particularly in neonates.

Category	Timing	Common Causes	Clinical Significance
Early Neonatal	First 24 hours of life	Hemolytic disease (Rh/ABO incompatibility), sepsis, intrauterine infections	Always pathological — requires urgent evaluation and treatment
Physiological	Days 2-7 (term), Days 3-10 (preterm)	Immature hepatic conjugation, increased bilirubin load, enhanced enterohepatic circulation	Common and usually benign; peaks day 3-5 in term infants
Prolonged Neonatal	Beyond 14 days (term) or 21 days (preterm)	Breast milk jaundice, hypothyroidism, biliary atresia, metabolic disorders	Requires investigation to exclude pathological causes, especially conjugated hyperbilirubinemia
Infantile/Childhood	Beyond neonatal period	Hepatitis, hemolytic disorders, choledochal cyst, Gilbert syndrome, metabolic liver disease	Always warrants investigation — not a normal finding after neonatal period

Critical Rule: Jaundice in the First 24 Hours

Jaundice appearing within the first 24 hours of life is NEVER physiological and always indicates a pathological process, most commonly hemolytic disease. This requires immediate investigation including total and direct bilirubin, blood type and Coombs test, complete blood count with reticulocyte count, and peripheral blood smear.

Classification by Type of Hyperbilirubinemia

Determining whether hyperbilirubinemia is predominantly unconjugated (indirect) or conjugated (direct) is essential for narrowing the differential diagnosis and guiding management.

Unconjugated (Indirect) Hyperbilirubinemia

Definition: Direct (conjugated) bilirubin less than 1 mg/dL when total bilirubin is less than 5 mg/dL, OR less than 20% of total bilirubin when total is higher.

Mechanisms:

Increased bilirubin production (hemolysis, polycythemia, sequestered blood)
Decreased hepatic uptake
Impaired conjugation (physiological immaturity, Gilbert syndrome, Crigler-Najjar syndrome)
Enhanced enterohepatic circulation

Concern: Risk of kernicterus at very high levels due to unconjugated bilirubin crossing the blood-brain barrier

Conjugated (Direct) Hyperbilirubinemia

Definition: Direct bilirubin greater than 1 mg/dL when total bilirubin is less than 5 mg/dL, OR greater than 20% of total bilirubin when total is higher.

Mechanisms:

Biliary obstruction (biliary atresia, choledochal cyst, gallstones)
Hepatocellular dysfunction (hepatitis, metabolic liver disease)
Intrahepatic cholestasis (Alagille syndrome, progressive familial intrahepatic cholestasis)

Concern: ALWAYS pathological — indicates hepatobiliary disease requiring prompt evaluation

Conjugated Hyperbilirubinemia is ALWAYS Pathological

Unlike unconjugated hyperbilirubinemia, which may be physiological in neonates, conjugated hyperbilirubinemia at any age indicates underlying hepatobiliary pathology. In neonates with prolonged jaundice, a fractionated bilirubin is mandatory to identify conjugated hyperbilirubinemia, as early diagnosis of conditions like biliary atresia significantly impacts outcomes. The Kasai procedure for biliary atresia has the best success rate when performed before 60 days of age.

Classification by Clinical Features

Feature	Description	Clinical Implications
Stool Color	Pale, clay-colored, or acholic stools	Suggests biliary obstruction (biliary atresia, choledochal cyst) — requires urgent evaluation
Urine Color	Dark urine (bilirubinuria)	Indicates conjugated hyperbilirubinemia — conjugated bilirubin is water-soluble and excreted in urine
Hepatomegaly	Enlarged liver on palpation	Suggests hepatocellular disease, storage disorders, or biliary obstruction
Splenomegaly	Enlarged spleen on palpation	Suggests hemolytic disease, portal hypertension, or infection
Failure to Thrive	Poor weight gain, growth deceleration	Indicates chronic liver disease, metabolic disorder, or malabsorption
Pruritus	Severe itching	Indicates cholestasis — bile salt accumulation in skin

Age-Specific Patterns of Jaundice

Age Group	Most Common Causes	Key Considerations
First 24 hours	Hemolytic disease (Rh, ABO), sepsis, TORCH infections	Always pathological — urgent evaluation required
Days 2-14	Physiological jaundice, breast milk jaundice, breastfeeding jaundice, hemolysis, sepsis	Most common period for benign jaundice; monitor for severity
Beyond 2 weeks (term)	Breast milk jaundice, biliary atresia, hypothyroidism, metabolic disorders	Must rule out conjugated hyperbilirubinemia and biliary atresia
Infants 2-12 months	Biliary atresia, choledochal cyst, hepatitis, metabolic liver disease	Often presents with cholestatic features; liver disease workup needed
Children 1-18 years	Viral hepatitis, autoimmune hepatitis, Wilson disease, Gilbert syndrome, hemolytic disorders	Hepatitis and hemolysis most common; Gilbert syndrome often diagnosed in adolescence

Key Concept: The “Rule of 2s” for Neonatal Jaundice Evaluation

First 24 hours: Always pathological — evaluate immediately
Beyond 2 weeks in term infants: Requires fractionated bilirubin to rule out conjugated hyperbilirubinemia
Beyond 3 weeks in preterm infants: Same evaluation as above
Any age with pale stools: Urgent evaluation for biliary obstruction

Impact on the Child and Family

Jaundice in neonates and children has significant implications beyond the immediate clinical presentation:

Hospital readmission: Hyperbilirubinemia is the leading cause of hospital readmission in the first week of life, affecting healthcare resource utilization and parental anxiety
Parental anxiety: The visible nature of jaundice and concerns about kernicterus can cause significant parental distress, requiring clear communication and education
Breastfeeding impact: Both breastfeeding jaundice (inadequate intake) and breast milk jaundice may lead to unnecessary cessation of breastfeeding if not managed appropriately
Long-term outcomes: Severe hyperbilirubinemia can result in permanent neurological sequelae (kernicterus), while cholestatic liver diseases may progress to cirrhosis and liver failure
Developmental monitoring: Children with a history of significant hyperbilirubinemia require developmental follow-up to assess for auditory and motor complications

2. Pathophysiology and Mechanisms

Understanding the underlying mechanisms of jaundice in pediatric patients

Understanding bilirubin metabolism is fundamental to evaluating and managing jaundice in children. Bilirubin is the end product of heme degradation, primarily from senescent red blood cells. The pathway from heme to bilirubin excretion involves multiple steps, each of which can be disrupted in various pathological conditions. In neonates, developmental immaturity of these pathways creates a physiological predisposition to jaundice, while in older children, jaundice typically reflects disruption of normally mature metabolic processes.

Bilirubin Metabolism Pathway

Step	Location	Process	Clinical Relevance
1. Bilirubin Production	Reticuloendothelial system (spleen, liver, bone marrow)	Heme from senescent red blood cells is converted to biliverdin by heme oxygenase, then to unconjugated bilirubin by biliverdin reductase	Increased production in hemolytic conditions, polycythemia, resorption of hematomas, ineffective erythropoiesis
2. Transport in Blood	Plasma	Unconjugated bilirubin binds to albumin for transport to the liver; free (unbound) bilirubin is lipid-soluble and neurotoxic	Hypoalbuminemia, acidosis, and certain drugs can displace bilirubin from albumin, increasing free bilirubin and neurotoxicity risk
3. Hepatic Uptake	Hepatocyte sinusoidal membrane	Bilirubin-albumin complex dissociates; unconjugated bilirubin enters hepatocyte via carrier-mediated transport (OATP transporters)	Impaired in Gilbert syndrome (reduced uptake), some drug interactions
4. Conjugation	Hepatocyte endoplasmic reticulum	UDP-glucuronosyltransferase (UGT1A1) conjugates bilirubin with glucuronic acid, forming water-soluble conjugated bilirubin	Immature in neonates; deficient in Gilbert syndrome (mild) and Crigler-Najjar syndrome (severe)
5. Biliary Excretion	Hepatocyte canalicular membrane	Conjugated bilirubin is actively secreted into bile canaliculi via MRP2 transporter	Impaired in Dubin-Johnson syndrome, intrahepatic cholestasis, biliary obstruction
6. Intestinal Processing	Small and large intestine	Conjugated bilirubin is deconjugated and reduced by gut bacteria to urobilinogen; most is excreted in stool as stercobilin	Enhanced enterohepatic circulation in neonates (sterile gut, increased beta-glucuronidase activity)

Developmental Differences in Neonates

Several physiological factors predispose neonates to developing hyperbilirubinemia, explaining why jaundice is so common in this age group:

Increased Bilirubin Production

Higher red blood cell mass: Neonatal hematocrit is 50-60% compared to 35-45% in older children
Shorter red blood cell lifespan: 70-90 days in neonates versus 120 days in adults
Higher rate of ineffective erythropoiesis: Contributing to increased heme turnover
Result: Bilirubin production is 2-3 times higher per kilogram in neonates than in adults

Decreased Bilirubin Elimination

Immature UGT1A1 activity: Only 1% of adult activity at birth, reaching adult levels by 14 weeks
Reduced hepatic uptake: Lower expression of hepatic transporter proteins
Enhanced enterohepatic circulation: Sterile neonatal gut lacks bacteria to convert bilirubin to urobilinogen
Increased intestinal beta-glucuronidase: Deconjugates bilirubin, allowing reabsorption

Mechanisms of Hyperbilirubinemia by Category

Unconjugated Hyperbilirubinemia

Mechanism	Conditions	Pathophysiology	Clinical Clues
Increased Production	Hemolytic disease of the newborn (Rh, ABO), G6PD deficiency, hereditary spherocytosis, pyruvate kinase deficiency, polycythemia, cephalohematoma, bruising	Accelerated red blood cell destruction or breakdown of sequestered blood overwhelms hepatic conjugation capacity	Anemia, reticulocytosis, positive Coombs test, splenomegaly, visible bruising or hematoma
Decreased Conjugation	Physiological jaundice, Gilbert syndrome, Crigler-Najjar syndrome types I and II, hypothyroidism	Reduced UGT1A1 enzyme activity leads to accumulation of unconjugated bilirubin	No hemolysis (normal hemoglobin and reticulocytes), no hepatomegaly, family history may be present
Enhanced Enterohepatic Circulation	Breast milk jaundice, breastfeeding jaundice, intestinal obstruction, pyloric stenosis	Increased intestinal reabsorption of unconjugated bilirubin; breast milk contains beta-glucuronidase and factors that inhibit UGT1A1	Breastfed infant, prolonged jaundice, normal stool color, otherwise well-appearing

Breastfeeding Jaundice vs. Breast Milk Jaundice

These are commonly confused but have different mechanisms:

Breastfeeding jaundice: Occurs in first week due to inadequate milk intake leading to dehydration, decreased stooling, and enhanced enterohepatic circulation. Managed by increasing feeding frequency and ensuring adequate intake.
Breast milk jaundice: Occurs after day 5-7 and may persist for weeks to months. Caused by substances in breast milk (beta-glucuronidase, non-esterified fatty acids) that increase intestinal bilirubin reabsorption and inhibit hepatic conjugation. Benign and does not require cessation of breastfeeding unless bilirubin levels are very high.

Conjugated Hyperbilirubinemia

Mechanism	Conditions	Pathophysiology	Clinical Clues
Biliary Obstruction (Extrahepatic)	Biliary atresia, choledochal cyst, inspissated bile syndrome, cholelithiasis, tumors	Physical obstruction prevents bile flow from liver to intestine; conjugated bilirubin refluxes into blood	Pale/acholic stools, dark urine, hepatomegaly, progressive jaundice; biliary atresia presents at 2-8 weeks
Intrahepatic Cholestasis	Alagille syndrome, progressive familial intrahepatic cholestasis (PFIC), alpha-1 antitrypsin deficiency, cystic fibrosis	Impaired bile formation or secretion within the liver due to hepatocyte dysfunction or bile duct paucity	Pruritus, hepatomegaly, failure to thrive, associated syndromic features (Alagille: cardiac, vertebral, facial)
Hepatocellular Injury	Viral hepatitis (hepatitis A, B, C), TORCH infections, neonatal hepatitis, autoimmune hepatitis, drug-induced hepatitis, Wilson disease	Hepatocyte damage impairs all aspects of bilirubin handling including uptake, conjugation, and excretion	Elevated transaminases, hepatomegaly, coagulopathy, possible encephalopathy in severe cases
Metabolic Liver Disease	Galactosemia, tyrosinemia, Niemann-Pick disease, Gaucher disease, glycogen storage disorders	Accumulation of toxic metabolites or substrates leads to hepatocyte injury and dysfunction	Hypoglycemia, coagulopathy, failure to thrive, hepatosplenomegaly, developmental delay, specific dietary triggers (galactosemia)
Infection	Sepsis, urinary tract infection, TORCH infections (toxoplasmosis, rubella, cytomegalovirus, herpes simplex)	Direct hepatocyte invasion, inflammatory cytokines, and cholestasis from endotoxins	Fever, lethargy, poor feeding, hepatosplenomegaly, thrombocytopenia, elevated inflammatory markers

Critical: Early Recognition of Biliary Atresia

Biliary atresia is a time-sensitive diagnosis. The Kasai portoenterostomy has the best outcomes when performed before 60 days of age:

Surgery before 60 days: approximately 70% achieve bile drainage
Surgery at 60-90 days: approximately 40% achieve bile drainage
Surgery after 90 days: less than 25% achieve bile drainage

Any neonate with prolonged jaundice (beyond 2 weeks) must have a fractionated bilirubin. If conjugated hyperbilirubinemia is present, urgent referral to pediatric gastroenterology/hepatology is mandatory.

Bilirubin Neurotoxicity

Unconjugated bilirubin is lipid-soluble and can cross the blood-brain barrier when free (unbound to albumin). This leads to bilirubin-induced neurological dysfunction (BIND):

Acute Bilirubin Encephalopathy

Early, potentially reversible phase of neurotoxicity:

Early phase: Lethargy, hypotonia, poor suck
Intermediate phase: Irritability, hypertonia, fever, high-pitched cry
Advanced phase: Opisthotonus, retrocollis, apnea, seizures, coma

Urgent exchange transfusion may prevent progression to permanent injury.

Kernicterus (Chronic Bilirubin Encephalopathy)

Permanent neurological sequelae from bilirubin deposition in basal ganglia, brainstem nuclei, and cerebellum:

Movement disorder: Athetoid cerebral palsy
Auditory dysfunction: Sensorineural hearing loss, auditory neuropathy
Oculomotor impairment: Upward gaze palsy
Dental enamel hypoplasia

Risk Factors for Bilirubin Neurotoxicity

Risk Factor	Mechanism
Prematurity	Immature blood-brain barrier, lower albumin levels, increased susceptibility of developing neurons
Hypoalbuminemia	Decreased bilirubin-binding capacity increases free bilirubin fraction
Acidosis	Decreases bilirubin-albumin binding affinity, increases free bilirubin
Sepsis	Inflammatory cytokines increase blood-brain barrier permeability; acidosis and hypoalbuminemia
Hemolysis	Rapid bilirubin production may overwhelm albumin-binding capacity
Drug displacement	Sulfonamides, ceftriaxone, and other drugs displace bilirubin from albumin
Asphyxia	Acidosis and blood-brain barrier disruption increase bilirubin entry into brain

Clinical Pearl: Conjugated Bilirubin is Not Neurotoxic

Unlike unconjugated bilirubin, conjugated bilirubin is water-soluble and does not cross the blood-brain barrier. Therefore, conjugated hyperbilirubinemia does not cause kernicterus. However, conjugated hyperbilirubinemia is always pathological and indicates significant hepatobiliary disease requiring investigation. The concern with conjugated hyperbilirubinemia is the underlying liver disease, not bilirubin neurotoxicity.

Pathophysiology Summary by Clinical Scenario

Scenario	Primary Mechanism	Typical Timing	Treatment Approach
Physiological jaundice	Immature conjugation + enhanced enterohepatic circulation + increased bilirubin load	Days 2-5 (peaks), resolves by day 7-10	Observation, phototherapy if levels exceed threshold
Hemolytic disease of newborn	Antibody-mediated red blood cell destruction (Rh, ABO incompatibility)	First 24 hours, rapidly progressive	Phototherapy, IVIG, exchange transfusion
G6PD deficiency	Oxidant stress-induced hemolysis + impaired hepatic conjugation	First 2-3 days, may be triggered	Phototherapy, avoid oxidant triggers, exchange if severe
Breast milk jaundice	Breast milk factors enhance enterohepatic circulation and inhibit conjugation	After day 5-7, may persist weeks	Continue breastfeeding, phototherapy rarely needed
Biliary atresia	Progressive destruction and obstruction of extrahepatic bile ducts	2-8 weeks of age, progressive	Kasai portoenterostomy before 60 days; liver transplant if unsuccessful
Neonatal hepatitis	Hepatocyte injury from viral, metabolic, or idiopathic causes	First weeks to months	Treat underlying cause, supportive care, monitor for progression

Understanding Why Specific Conditions Cause Jaundice

Why does ABO incompatibility cause less severe hemolysis than Rh disease?

ABO incompatibility (typically type O mother with type A or B infant) produces milder hemolysis because:

Anti-A and anti-B antibodies are predominantly IgM, which does not cross the placenta efficiently
A and B antigens are expressed on many tissues, not just red blood cells, diluting the antibody effect
Fetal red blood cells have fewer A and B antigen sites than adult red blood cells

Why does phototherapy work?

Phototherapy (blue light at 460-490 nm wavelength) works through three mechanisms:

Photo-isomerization: Converts bilirubin to water-soluble isomers (lumirubin) that can be excreted in bile and urine without conjugation
Structural isomerization: Creates configurational isomers that are less lipophilic
Photo-oxidation: Minor contribution through breakdown of bilirubin to colorless products

3. History Taking

A comprehensive approach to eliciting the jaundice history in pediatric patients

Red Flags — Require Urgent Evaluation

Neonatal Red Flags:

Jaundice in first 24 hours — Always pathological (hemolysis, sepsis)
Rapidly rising bilirubin — Greater than 0.2 mg/dL/hour suggests hemolysis
Pale or acholic stools — Biliary obstruction (biliary atresia)
Dark urine — Conjugated hyperbilirubinemia
Prolonged jaundice beyond 2 weeks (term) — Requires fractionated bilirubin
Lethargy, poor feeding, hypotonia — Early bilirubin encephalopathy

All Ages Red Flags:

High-pitched cry, opisthotonus — Acute bilirubin encephalopathy
Hepatomegaly with firm liver — Liver disease, biliary obstruction
Splenomegaly — Hemolysis, portal hypertension, infection
Failure to thrive — Chronic liver disease, metabolic disorder
Bleeding or bruising — Coagulopathy from liver failure
Altered mental status — Hepatic encephalopathy, kernicterus
Fever with jaundice — Sepsis, cholangitis, hepatitis

Systematic History: The “YELLOW” Approach

Use the mnemonic “YELLOW” to ensure comprehensive history taking for pediatric jaundice:

Y — Yesterday or Years: When did jaundice first appear? First 24 hours is always pathological. Duration helps classify as acute, prolonged, or chronic.
E — Excretions: What color are the stools and urine? Pale stools and dark urine indicate conjugated hyperbilirubinemia and possible biliary obstruction.
L — Labor and Delivery: Birth history including gestational age, delivery complications, bruising, cephalohematoma, Apgar scores, and need for resuscitation.
L — Lineage and Labs: Family history of jaundice, anemia, splenectomy, liver disease, metabolic disorders. Maternal blood type and antibody screen results.
O — Oral Intake: Feeding history — breastfeeding adequacy, formula type, weight gain, number of wet diapers and stools per day.
W — Warning Signs: Associated symptoms including lethargy, fever, poor feeding, irritability, vomiting, bleeding, itching, or developmental concerns.

Age-Specific History Components

Neonatal History (0-28 days)

Category	Key Questions	Clinical Significance
Timing of Onset	“When did you first notice the yellow color?” “Was baby yellow at birth or in the first day?”	First 24 hours = pathological (hemolysis, sepsis). Days 2-5 = likely physiological. Beyond 2 weeks = requires investigation.
Progression	“Is the jaundice getting worse, staying the same, or improving?” “Has it spread from face to body to legs?”	Cephalocaudal progression correlates with bilirubin level. Rapid progression suggests hemolysis.
Stool Color	“What color are baby’s stools?” “Have you noticed any pale, white, or clay-colored stools?”	Acholic stools are a critical finding suggesting biliary obstruction. Use stool color card if available.
Urine Color	“What color is baby’s urine?” “Does it stain the diaper dark yellow or brown?”	Dark urine indicates bilirubinuria (conjugated hyperbilirubinemia). Normal neonatal urine is pale yellow.
Feeding	“How is baby feeding?” “How many times per day?” “How long at each breast?” “How many wet diapers and stools per day?”	Poor intake increases enterohepatic circulation. Adequate feeding: 8-12 feeds/day, 6+ wet diapers, 3-4 stools/day by day 4.
Weight	“What was baby’s birth weight?” “What is the current weight?” “Has baby been weighed recently?”	Greater than 7% weight loss by day 3 or greater than 10% maximum suggests inadequate intake (breastfeeding jaundice).
Behavior	“Is baby alert and active?” “Does baby wake for feeds?” “Have you noticed unusual sleepiness, high-pitched crying, or arching?”	Lethargy, poor feeding, hypotonia, high-pitched cry, and opisthotonus are signs of bilirubin encephalopathy.

Birth and Perinatal History

Category	Key Questions	Clinical Significance
Gestational Age	“How many weeks pregnant were you when baby was born?” “Was baby premature?”	Preterm infants have more immature conjugation and higher risk of hyperbilirubinemia and neurotoxicity.
Delivery	“Was it a vaginal delivery or cesarean section?” “Were there any complications?” “Was vacuum or forceps used?”	Instrumental delivery increases risk of cephalohematoma and bruising, leading to increased bilirubin load.
Birth Trauma	“Did baby have any bruising at birth?” “Was there a bump on baby’s head (cephalohematoma)?”	Sequestered blood from bruising or cephalohematoma is broken down to bilirubin, increasing load.
Maternal Blood Type	“What is your blood type?” “Do you know if you are Rh positive or negative?” “Were there any antibody concerns during pregnancy?”	Rh-negative mother with Rh-positive baby = risk of Rh hemolytic disease. Type O mother = risk of ABO incompatibility.
Maternal Infections	“Did you have any infections during pregnancy?” “Were you tested for infections like hepatitis B, HIV, or syphilis?”	TORCH infections (toxoplasmosis, rubella, cytomegalovirus, herpes) can cause neonatal hepatitis and jaundice.
Maternal Medications	“Did you take any medications during pregnancy?” “Any herbal supplements?”	Certain medications cross placenta and may affect bilirubin metabolism or cause hemolysis.
Prenatal Care	“Did you receive prenatal care?” “Were there any concerns on ultrasound?”	Prenatal ultrasound may have identified hepatomegaly, ascites, or hydrops suggesting severe hemolytic disease.

Infant and Childhood History (Beyond Neonatal Period)

Category	Key Questions	Clinical Significance
Duration and Pattern	“How long has your child been jaundiced?” “Is it constant or does it come and go?” “Has it been getting worse?”	Acute onset suggests hepatitis or hemolysis. Chronic/progressive suggests biliary or metabolic disease.
Associated Symptoms	“Has your child had fever, abdominal pain, nausea, vomiting, or fatigue?” “Any itching?”	Pruritus indicates cholestasis. Fever and abdominal pain suggest hepatitis or cholangitis.
Stool and Urine	“What color are the stools?” “Is the urine darker than usual?”	Pale stools + dark urine = cholestasis/obstruction. Normal stools + normal urine = likely unconjugated.
Growth	“Has your child been growing well?” “Any concerns about weight gain?” “Has there been weight loss?”	Failure to thrive suggests chronic liver disease, metabolic disorder, or malabsorption from cholestasis.
Development	“Is your child meeting developmental milestones?” “Any concerns about development?”	Developmental delay may indicate metabolic disease (galactosemia, tyrosinemia) or previous bilirubin encephalopathy.
Diet	“What does your child eat?” “Any dietary restrictions?” “When did you introduce solid foods?”	Galactosemia worsens with milk intake. Fructose intolerance with fruit/sucrose. Wilson disease presents after age 3-5.
Exposures	“Has your child been exposed to anyone with hepatitis or other liver disease?” “Any recent travel?” “Any sick contacts?”	Hepatitis A from contaminated food/water, hepatitis B/C from vertical transmission or blood exposure.

Targeted Questions by Suspected Cause

Suspected Cause	Key Features	Ask This Question
Hemolytic disease of the newborn	Early onset (first 24 hours), rapid progression, anemia, hepatosplenomegaly	“What is your blood type? Did doctors mention any blood type incompatibility or antibodies during pregnancy?”
G6PD deficiency	Triggered hemolysis, family history, ethnic background (Mediterranean, African, Asian)	“Has baby been exposed to mothballs, fava beans, or any new medications? Is there a family history of anemia or jaundice?”
Breast milk jaundice	Exclusively breastfed, onset after day 5-7, prolonged but otherwise well	“Is baby exclusively breastfed? Is baby feeding well and gaining weight? Is baby otherwise healthy and active?”
Breastfeeding jaundice	First week, poor feeding, weight loss, decreased stooling	“How often is baby feeding? How many wet diapers per day? Has baby lost weight? How many stools per day?”
Biliary atresia	Onset 2-8 weeks, progressive jaundice, pale stools, dark urine, hepatomegaly	“What color are baby’s stools? Have you noticed pale, clay-colored, or white stools? Is the urine dark?”
Hypothyroidism	Prolonged jaundice, poor feeding, constipation, hypotonia, large fontanelle	“Did baby have a newborn screening test? Has baby been constipated? Does baby seem floppy or have a weak cry?”
Sepsis/Infection	Fever or hypothermia, lethargy, poor feeding, irritability	“Has baby had any fever or felt cold? Is baby more sleepy than usual? Has feeding changed? Any respiratory symptoms?”
Galactosemia	Vomiting after feeds, failure to thrive, hepatomegaly, cataracts, sepsis	“Does baby vomit after feeding milk? Has baby had any serious infections? Are there any eye problems?”
Viral hepatitis	Fever, malaise, anorexia, abdominal pain, dark urine, pale stools	“Has your child had fever, loss of appetite, or stomach pain? Any sick contacts? Any recent travel?”
Autoimmune hepatitis	Older children/adolescents, fatigue, joint pain, other autoimmune conditions	“Does your child have any other health conditions? Any joint pain or rashes? Family history of autoimmune diseases?”
Wilson disease	Age greater than 3 years, neuropsychiatric symptoms, Kayser-Fleischer rings	“Has your child had any changes in behavior, school performance, or handwriting? Any tremor or difficulty with movement?”
Gilbert syndrome	Adolescent, intermittent mild jaundice, triggered by fasting/stress/illness	“Does the jaundice come and go? Is it worse when your child is sick, stressed, or hasn’t eaten? Family history of similar episodes?”

Family History

Conditions to Ask About

Neonatal jaundice: “Did any siblings or family members have jaundice as babies requiring treatment?”
Anemia or hemolytic disorders: “Is there any family history of anemia, sickle cell disease, thalassemia, or spherocytosis?”
Splenectomy: “Has anyone in the family had their spleen removed?”
Liver disease: “Is there any family history of liver problems, cirrhosis, or liver transplant?”
Metabolic disorders: “Are there any inherited metabolic conditions in the family?”
Consanguinity: “Are the parents related by blood?” (increases risk of autosomal recessive conditions)

Ethnic Background Considerations

G6PD deficiency: More common in Mediterranean, African, Middle Eastern, and Southeast Asian populations
Sickle cell disease: African, Mediterranean, Middle Eastern, Indian descent
Thalassemia: Mediterranean, Southeast Asian, Middle Eastern, African descent
Hereditary spherocytosis: Northern European descent
Crigler-Najjar syndrome: Increased in certain isolated populations
Wilson disease: All ethnicities, but certain mutations more common in specific populations

Medication and Exposure History

Medications That May Cause or Worsen Jaundice

Ceftriaxone: Displaces bilirubin from albumin — contraindicated in jaundiced neonates
Sulfonamides: Displace bilirubin from albumin binding
Acetaminophen (overdose): Hepatotoxicity
Valproic acid: Hepatotoxicity
Isoniazid: Hepatotoxicity
Erythromycin estolate: Cholestatic hepatitis
Herbal supplements: Various hepatotoxic effects

Exposures in G6PD Deficiency

Naphthalene (mothballs): Can trigger severe hemolysis
Fava beans: Can cause hemolytic crisis
Henna: Applied to skin in some cultures
Primaquine and other antimalarials: Hemolytic trigger
Sulfonamides: Hemolytic trigger
Nitrofurantoin: Hemolytic trigger
Methylene blue: Used in some medical procedures

Clinical Pearl: The Stool Color Card

The stool color card is an invaluable screening tool for biliary atresia. Parents compare their baby’s stool to standardized color images. Pale, acholic (clay-colored) stools warrant immediate investigation. In countries where stool color cards are routinely provided to parents (such as Taiwan and Japan), earlier diagnosis of biliary atresia has significantly improved outcomes. Always ask parents to describe or show you the stool color, and provide a stool color card when evaluating prolonged neonatal jaundice.

4. Physical Examination

A systematic head-to-toe approach for jaundice in pediatric patients

Systematic Framework: Use the “Head to Extremities” approach for complete examination of pediatric patients presenting with jaundice. Pay particular attention to the liver and spleen, neurological status (in neonates), and signs of chronic liver disease.

General Inspection

Overall appearance: Well or ill-appearing? Alert or lethargic? Active or listless?
Nutritional status: Well-nourished or wasted? Signs of failure to thrive?
Jaundice assessment: Yellow discoloration of skin and sclera; assess in natural light
Skin color: Note any pallor (anemia), plethora (polycythemia), or bronze discoloration (phototherapy)
Activity level: Age-appropriate activity? Spontaneous movement?
Cry (in infants): Normal cry or high-pitched cry (concerning for encephalopathy)?
Dysmorphic features: May suggest syndromic causes (Alagille syndrome, Down syndrome)

Assessing Jaundice Severity by Visual Inspection

Kramer’s Rule for Estimating Bilirubin

Jaundice progresses in a cephalocaudal (head-to-toe) direction as bilirubin levels rise. While visual estimation is imprecise and should not replace laboratory measurement, it provides a useful initial assessment:

Zone	Area of Jaundice	Estimated Bilirubin Level
Zone 1	Head and neck only	Approximately 5-7 mg/dL
Zone 2	Upper trunk (above umbilicus)	Approximately 7-10 mg/dL
Zone 3	Lower trunk and thighs	Approximately 10-13 mg/dL
Zone 4	Arms and lower legs	Approximately 13-16 mg/dL
Zone 5	Hands and feet (palms/soles)	Greater than 15 mg/dL

Important: Visual assessment is less reliable in dark-skinned infants, under artificial lighting, and after phototherapy. Always confirm with transcutaneous or serum bilirubin measurement.

Vital Signs

Age	Heart Rate (bpm)	Respiratory Rate (/min)	Systolic BP (mmHg)	Temperature
Neonate (0-28 days)	100-160	30-60	60-90	36.5-37.5°C
Infant (1-12 months)	100-150	25-40	80-100	36.5-37.5°C
Toddler (1-3 years)	90-140	20-30	90-105	36.5-37.5°C
Preschool (3-5 years)	80-120	20-25	95-110	36.5-37.5°C
School age (6-12 years)	70-110	18-22	100-120	36.5-37.5°C
Adolescent (12-18 years)	60-100	12-20	110-130	36.5-37.5°C

Vital Sign Abnormality	Clinical Significance in Jaundiced Child
Fever	Suggests infection (sepsis, urinary tract infection, cholangitis, hepatitis)
Hypothermia (neonates)	May indicate sepsis — more common than fever in neonates
Tachycardia	Anemia (hemolysis), dehydration, sepsis, fever
Tachypnea	Metabolic acidosis, sepsis, pulmonary edema (hepatopulmonary syndrome)
Hypotension	Septic shock, decompensated liver failure

Growth Parameters

Essential in All Jaundiced Children: Plot weight, length/height, and head circumference on appropriate growth charts.

Weight loss greater than 7% in first 3 days: Suggests inadequate feeding (breastfeeding jaundice)
Weight loss greater than 10% at any time: Significant dehydration requiring intervention
Failure to thrive: Suggests chronic liver disease, metabolic disorder, or malabsorption
Crossing percentiles downward: Concerning for progressive disease

Head and Neck Examination

Eyes

Scleral icterus: Best assessed in natural light; often the first visible sign of jaundice
Conjunctival pallor: Indicates anemia (hemolysis)
Kayser-Fleischer rings: Brownish-green rings at corneal limbus — pathognomonic for Wilson disease (requires slit-lamp examination)
Cataracts: May indicate galactosemia (oil drop cataracts) or congenital rubella
Chorioretinitis: Suggests congenital infection (TORCH)

Head (Neonates)

Anterior fontanelle: Bulging (increased intracranial pressure, meningitis), sunken (dehydration), or large (hypothyroidism)
Cephalohematoma: Subperiosteal blood collection — source of increased bilirubin load; limited to one cranial bone
Caput succedaneum: Scalp edema crossing suture lines — less significant for jaundice
Microcephaly: May suggest congenital infection

Face

Dysmorphic features of Alagille syndrome: Triangular face, broad forehead, deep-set eyes, pointed chin, bulbous nose
Coarse facies: May suggest storage disorders

Mouth

Large tongue: Hypothyroidism
Dry mucous membranes: Dehydration

Skin Examination

Finding	Description	Clinical Significance
Jaundice	Yellow discoloration of skin; blanch skin to assess underlying color	Assess extent using Kramer’s zones; more extensive = higher bilirubin
Pallor	Pale skin, pale conjunctivae, pale palmar creases	Anemia — suggests hemolysis or chronic disease
Plethora	Ruddy, red skin color	Polycythemia — increased bilirubin production from increased red cell mass
Bruising	Ecchymoses, petechiae	May be source of bilirubin load (bruising) or indicate coagulopathy (liver failure)
Petechiae/Purpura	Small non-blanching spots	Congenital infection (TORCH), liver failure with thrombocytopenia
Bronze discoloration	Bronze-colored skin	“Bronze baby syndrome” — rare complication of phototherapy in cholestatic jaundice
Excoriations	Scratch marks on skin	Pruritus from cholestasis — bile salt deposition in skin
Spider angiomata	Central arteriole with radiating vessels; blanch with pressure	Sign of chronic liver disease (rare in young children)
Xanthomas	Yellow papules or plaques	Chronic cholestasis with hypercholesterolemia (Alagille syndrome)

Abdominal Examination

The abdominal examination is critical in evaluating pediatric jaundice, as it provides key information about liver size, spleen size, and evidence of portal hypertension.

Inspection

Abdominal distension: Ascites, hepatosplenomegaly, or intestinal obstruction
Visible veins: Caput medusae indicates portal hypertension (rare in children)
Umbilical hernia: Common in hypothyroidism
Surgical scars: Previous abdominal surgery

Palpation — Liver

Normal Liver Size by Age

The liver is normally palpable in infants and young children. Measure from the right costal margin in the midclavicular line:

Neonates: 1-2 cm below costal margin is normal
Infants: 1-2 cm below costal margin is normal
Children 1-5 years: Up to 2 cm below costal margin may be normal
Children older than 5 years: Usually not palpable or just at costal margin

Liver Finding	Description	Suggests
Hepatomegaly — soft	Enlarged liver with soft, smooth edge	Acute hepatitis, congestion, early storage disease
Hepatomegaly — firm	Enlarged liver with firm edge	Biliary obstruction, fibrosis, chronic liver disease
Hepatomegaly — hard/nodular	Enlarged liver with hard, irregular surface	Cirrhosis, tumor (very rare in children)
Tender hepatomegaly	Pain on palpation of enlarged liver	Acute hepatitis, rapid hepatic congestion, cholangitis
Small/non-palpable liver	Liver smaller than expected or shrunken	End-stage cirrhosis with hepatic atrophy, acute liver failure

Palpation — Spleen

Finding	Clinical Significance
Splenomegaly	Hemolytic disorders (hereditary spherocytosis, thalassemia), portal hypertension, infection (congenital infection, sepsis), storage disorders
Massive splenomegaly	Storage disorders (Gaucher, Niemann-Pick), severe portal hypertension, hematological malignancy
Combined hepatosplenomegaly	Congenital infection, storage disorders, hemolytic disease, portal hypertension

Other Abdominal Findings

Ascites: Fluid wave, shifting dullness — indicates portal hypertension or liver failure
Right upper quadrant mass: May indicate choledochal cyst
Olive-shaped mass (pylorus): Pyloric stenosis — can cause unconjugated hyperbilirubinemia

Neurological Examination (Critical in Neonates)

Signs of Acute Bilirubin Encephalopathy

Early recognition of bilirubin neurotoxicity is critical. The progression through three phases:

Phase	Signs	Reversibility
Early (Days 1-2)	Lethargy, hypotonia, poor suck, decreased Moro reflex	Potentially reversible with urgent treatment
Intermediate	Irritability, hypertonia, fever, high-pitched cry, retrocollis (neck extension)	May be reversible with immediate intervention
Advanced	Opisthotonus, seizures, apnea, coma, death	Irreversible damage likely; survivors have kernicterus

Neurological Assessment Components

Level of alertness: Alert, drowsy, lethargic, or unresponsive
Tone: Hypotonia (early encephalopathy) or hypertonia (intermediate/advanced)
Primitive reflexes: Moro, suck, grasp — diminished in encephalopathy
Cry: Normal, weak, or high-pitched (shrill cry is concerning)
Posture: Normal flexion, opisthotonus (arching), or retrocollis (neck hyperextension)
Feeding ability: Strong suck, weak suck, or unable to suck

Cardiovascular Examination

Heart murmur: May indicate congenital heart disease associated with Alagille syndrome (peripheral pulmonary stenosis is classic)
Tachycardia: Anemia, fever, sepsis, dehydration
Signs of heart failure: Hepatomegaly, edema, gallop rhythm — hepatic congestion can cause jaundice

Signs of Chronic Liver Disease

While more common in older children with longstanding liver disease, these signs should be sought:

Skin and Nails

Spider angiomata
Palmar erythema
Clubbing
Leukonychia (white nails)
Xanthomas
Excoriations (pruritus)

Other Signs

Ascites
Peripheral edema
Muscle wasting
Gynecomastia (older males)
Bruising/bleeding
Fetor hepaticus (sweet, musty breath)

Summary: Expected Findings by Etiology

Condition	General Appearance	Liver/Spleen	Other Key Findings
Physiological jaundice	Well-appearing, active, feeding well	Normal	Jaundice limited to face/upper body; normal stools
Hemolytic disease	Pallor, may be ill-appearing if severe	Hepatosplenomegaly	Tachycardia, pallor, extensive jaundice, positive Coombs
Breast milk jaundice	Well-appearing, thriving	Normal	Prolonged but benign jaundice; normal stools and urine
Breastfeeding jaundice	May appear dehydrated, weight loss	Normal	Poor feeding, decreased wet diapers and stools
Biliary atresia	Initially well, progressive failure to thrive	Hepatomegaly (firm liver)	Acholic (pale) stools, dark urine, progressive jaundice
Sepsis	Ill-appearing, lethargic, temperature instability	Hepatomegaly (may be tender)	Fever/hypothermia, poor perfusion, respiratory distress
Hypothyroidism	Large fontanelle, umbilical hernia, hypotonia	Normal or mild hepatomegaly	Constipation, prolonged jaundice, macroglossia, lethargy
Galactosemia	Failure to thrive, vomiting	Hepatomegaly	Cataracts, hypoglycemia, E. coli sepsis, developmental delay
Alagille syndrome	Characteristic facies, failure to thrive	Hepatomegaly	Cardiac murmur, butterfly vertebrae, xanthomas, pruritus
Wilson disease	Older child, neuropsychiatric symptoms	Hepatomegaly or cirrhotic liver	Kayser-Fleischer rings, tremor, behavioral changes

Important Teaching Point

Normal examination is common in certain conditions: Many causes of neonatal jaundice, including physiological jaundice, breast milk jaundice, and Gilbert syndrome, present with entirely normal physical examination findings except for jaundice itself. However, a normal examination does not exclude serious pathology. The combination of history (timing, feeding, stool and urine color) and laboratory evaluation is essential for accurate diagnosis. Always check stool color in prolonged neonatal jaundice — a single acholic stool warrants urgent investigation.

5. Differential Diagnosis

Systematic approach organized by probability, age, and type of hyperbilirubinemia

The differential diagnosis of jaundice in pediatric patients is best approached by considering the age of the patient, the type of hyperbilirubinemia (unconjugated versus conjugated), and the clinical context. This systematic approach allows efficient narrowing of possibilities and appropriate investigation.

Critical First Step: Determine the Type of Hyperbilirubinemia

Before proceeding with the differential diagnosis, obtain a fractionated (total and direct) bilirubin:

Unconjugated (indirect) predominant: Direct bilirubin less than 1 mg/dL (if total less than 5 mg/dL) OR less than 20% of total bilirubin
Conjugated (direct) predominant: Direct bilirubin greater than 1 mg/dL (if total less than 5 mg/dL) OR greater than 20% of total bilirubin

This distinction fundamentally changes the differential diagnosis and urgency of evaluation.

Neonatal Jaundice (0-28 days): Unconjugated Hyperbilirubinemia

By Timing of Onset

Timing	Probability	Condition	Key Features	Red Flags
First 24 Hours (ALWAYS PATHOLOGICAL)	COMMON	Hemolytic disease of the newborn (ABO incompatibility)	Mother type O, baby type A or B; mild to moderate hemolysis	Rapidly rising bilirubin, anemia
	LESS COMMON	Hemolytic disease of the newborn (Rh incompatibility)	Rh-negative mother, Rh-positive baby; can be severe	Severe anemia, hydrops, positive Coombs
	LESS COMMON	G6PD deficiency	Mediterranean, African, Asian descent; may be triggered	Rapid rise, Heinz bodies on smear
	UNCOMMON	Sepsis, congenital infection	Ill-appearing, temperature instability	Lethargy, poor feeding, fever/hypothermia
Days 2-7	VERY COMMON (60-80%)	Physiological jaundice	Peaks day 3-5, resolves by day 7-10; baby well	None if within normal limits
	COMMON	Breastfeeding jaundice	Inadequate intake, weight loss, decreased stooling	Greater than 7% weight loss, dehydration
	LESS COMMON	ABO incompatibility	May present or worsen in this period	Anemia, reticulocytosis
	LESS COMMON	Cephalohematoma/bruising	History of traumatic delivery; visible hematoma	Large hematoma, extensive bruising
	LESS COMMON	Polycythemia	Infant of diabetic mother, SGA, delayed cord clamping	Plethora, hematocrit greater than 65%
Beyond 2 Weeks (Prolonged Jaundice)	COMMON (if unconjugated)	Breast milk jaundice	Exclusively breastfed, well, thriving, normal stools	None — diagnosis of exclusion
	LESS COMMON	Hypothyroidism	Prolonged jaundice, constipation, hypotonia, large fontanelle	Check newborn screening result
	LESS COMMON	G6PD deficiency	May cause prolonged unconjugated jaundice	Family history, ethnic background
	UNCOMMON	Gilbert syndrome	Mild unconjugated hyperbilirubinemia; usually diagnosed later	Family history
	RARE	Crigler-Najjar syndrome type II	Moderate unconjugated hyperbilirubinemia; responds to phenobarbital	Persistent elevation despite treatment
	VERY RARE	Crigler-Najjar syndrome type I	Severe unconjugated hyperbilirubinemia; no response to phenobarbital	Very high bilirubin, kernicterus risk

Neonatal and Infant Jaundice: Conjugated Hyperbilirubinemia

Conjugated Hyperbilirubinemia is ALWAYS Pathological

Any infant with conjugated hyperbilirubinemia requires urgent evaluation. Early diagnosis of biliary atresia is critical — the Kasai procedure has the best outcomes when performed before 60 days of age.

Probability	Condition	Approximate Frequency	Key Features	Urgent Action
COMMON	Biliary atresia	25-40% of neonatal cholestasis	Progressive jaundice, acholic stools, dark urine, hepatomegaly	Urgent ultrasound and HIDA scan; surgical consultation
COMMON	Idiopathic neonatal hepatitis	25-30% of neonatal cholestasis	Jaundice, hepatomegaly, variable stool color	Exclude other causes; supportive care
LESS COMMON	Congenital infections (TORCH)	5-10% of neonatal cholestasis	Hepatosplenomegaly, petechiae, growth restriction, other organ involvement	TORCH serologies, urine CMV
LESS COMMON	Alpha-1 antitrypsin deficiency	5-10% of neonatal cholestasis	Prolonged jaundice, hepatomegaly; may have respiratory symptoms later	Alpha-1 antitrypsin level and phenotype
LESS COMMON	Choledochal cyst	2-5% of neonatal cholestasis	Jaundice, abdominal mass, may have intermittent symptoms	Ultrasound; surgical consultation
LESS COMMON	Alagille syndrome	2-5% of neonatal cholestasis	Characteristic facies, cardiac murmur, butterfly vertebrae	Cardiac echo, spine X-ray, genetic testing
UNCOMMON	Galactosemia	1-2%	Vomiting, failure to thrive, hepatomegaly, cataracts, E. coli sepsis	Stop lactose immediately; galactose-1-phosphate uridyltransferase assay
UNCOMMON	Tyrosinemia type I	Rare	Liver failure, coagulopathy, renal tubular dysfunction, cabbage-like odor	Urine succinylacetone, start nitisinone if confirmed
UNCOMMON	Progressive familial intrahepatic cholestasis (PFIC)	Rare	Severe pruritus, low or normal GGT (PFIC1, PFIC2), hepatomegaly	GGT level, genetic testing
UNCOMMON	Cystic fibrosis	Rare as primary presentation	Meconium ileus, failure to thrive, respiratory symptoms	Sweat chloride test, genetic testing
RARE	Neonatal hemochromatosis	Very rare	Acute liver failure, hypoglycemia, coagulopathy	Ferritin, MRI for iron deposition, exchange transfusion/IVIG
RARE	Bile acid synthesis defects	Very rare	Progressive cholestasis, fat-soluble vitamin deficiency	Urine bile acid analysis, genetic testing

Childhood Jaundice (Beyond Infancy)

Probability	Condition	Type	Age Group	Key Features
COMMON	Viral hepatitis (Hepatitis A)	Conjugated	Any age	Fever, malaise, anorexia, abdominal pain, dark urine; often epidemic
COMMON	Gilbert syndrome	Unconjugated	Adolescents	Mild, intermittent jaundice; worse with fasting, stress, illness; benign
LESS COMMON	Hemolytic anemia (hereditary spherocytosis)	Unconjugated	Any age	Anemia, splenomegaly, family history, gallstones
LESS COMMON	Autoimmune hepatitis	Conjugated/Mixed	Older children, adolescents	Fatigue, elevated transaminases, autoantibodies, other autoimmune conditions
LESS COMMON	Viral hepatitis (Hepatitis B, C)	Conjugated	Any age	Often chronic/asymptomatic; vertical transmission or blood exposure
LESS COMMON	Epstein-Barr virus hepatitis	Conjugated	Adolescents	Infectious mononucleosis syndrome, lymphadenopathy, splenomegaly
UNCOMMON	Wilson disease	Conjugated/Mixed	Greater than 3-5 years	Neuropsychiatric symptoms, Kayser-Fleischer rings, low ceruloplasmin
UNCOMMON	Drug-induced liver injury	Conjugated	Any age	History of medication use (acetaminophen, valproate, isoniazid, etc.)
UNCOMMON	Cholelithiasis/Choledocholithiasis	Conjugated	Older children	Abdominal pain, may be associated with hemolytic disorders
RARE	Primary sclerosing cholangitis	Conjugated	Older children	Often associated with inflammatory bowel disease; elevated GGT and ALP

Anatomical Approach to Jaundice

Pre-Hepatic (Increased Production)

Hemolytic disease of newborn

G6PD deficiency

Hereditary spherocytosis

Thalassemia

Sickle cell disease

Polycythemia

Sequestered blood (cephalohematoma)

→ Unconjugated hyperbilirubinemia

Hepatic (Impaired Conjugation/Uptake)

Physiological jaundice

Breast milk jaundice

Gilbert syndrome

Crigler-Najjar syndrome

Hypothyroidism

Neonatal hepatitis

Metabolic liver disease

→ Unconjugated (conjugation defects) or Conjugated (hepatocellular)

Hepatocellular (Liver Cell Injury)

Viral hepatitis (A, B, C, EBV, CMV)

Autoimmune hepatitis

Wilson disease

Alpha-1 antitrypsin deficiency

Drug-induced hepatitis

TORCH infections

Galactosemia, tyrosinemia

→ Conjugated (or mixed) hyperbilirubinemia

Post-Hepatic (Biliary Obstruction)

Biliary atresia

Choledochal cyst

Cholelithiasis

Inspissated bile syndrome

Primary sclerosing cholangitis

Tumors (rare)

Alagille syndrome (bile duct paucity)

→ Conjugated hyperbilirubinemia

Drug-Induced Causes of Jaundice in Children

Drug/Agent	Mechanism	Type of Jaundice	Clinical Features
Acetaminophen (overdose)	Direct hepatotoxicity	Conjugated (hepatocellular)	Acute liver failure, very high transaminases, coagulopathy
Valproic acid	Idiosyncratic hepatotoxicity	Conjugated (hepatocellular)	Hyperammonemia, elevated transaminases, may be fatal
Isoniazid	Metabolite-induced hepatotoxicity	Conjugated (hepatocellular)	Elevated transaminases, usually reversible on discontinuation
Erythromycin estolate	Cholestatic injury	Conjugated (cholestatic)	Abdominal pain, elevated ALP and GGT
Amoxicillin-clavulanate	Cholestatic/mixed injury	Conjugated	Delayed onset (weeks after exposure), cholestatic pattern
Sulfonamides	Bilirubin displacement from albumin; hepatotoxicity	Unconjugated (displacement) or Conjugated (hepatitis)	Avoid in neonates; increased kernicterus risk
Ceftriaxone	Bilirubin displacement from albumin; biliary sludge	Unconjugated (displacement) or Conjugated (sludge)	Contraindicated in jaundiced neonates; can cause biliary pseudolithiasis
Total parenteral nutrition	Cholestasis (multifactorial)	Conjugated	Premature infants on prolonged TPN; may progress to cirrhosis
Herbal supplements	Variable hepatotoxicity	Variable	Difficult to identify; always ask about alternative medicines
G6PD triggers (naphthalene, fava beans)	Oxidant-induced hemolysis	Unconjugated	Acute hemolysis in G6PD-deficient patients

Quick Reference: “If You See This, Think This”

Clinical Clue	Think This First	Next Step
Jaundice in first 24 hours	Hemolytic disease (Rh, ABO, G6PD)	Urgent: Blood type, Coombs, CBC, reticulocytes, bilirubin
Pale/acholic stools + dark urine	Biliary atresia (until proven otherwise)	Urgent: Fractionated bilirubin, ultrasound, HIDA scan
Prolonged jaundice beyond 2 weeks + well baby	Breast milk jaundice (if unconjugated)	Fractionated bilirubin to exclude conjugated hyperbilirubinemia
Jaundice + hepatosplenomegaly	Hemolysis, TORCH infection, storage disorder	CBC with smear, Coombs, TORCH serologies, metabolic workup
Jaundice + poor feeding + lethargy	Sepsis, metabolic disease, bilirubin encephalopathy	Septic workup, glucose, ammonia, lactate, urgent bilirubin
Jaundice + vomiting after milk feeds	Galactosemia	Stop lactose immediately; galactose-1-phosphate uridyltransferase assay
Jaundice + cataracts	Galactosemia, congenital rubella	Metabolic screen, TORCH serologies
Jaundice + characteristic facies + heart murmur	Alagille syndrome	Echocardiogram, spine X-ray, ophthalmology, genetic testing
Jaundice + constipation + hypotonia + large fontanelle	Congenital hypothyroidism	Check newborn screening; TSH and free T4
Adolescent + intermittent mild jaundice	Gilbert syndrome	Confirm unconjugated hyperbilirubinemia, normal liver tests
Jaundice + neuropsychiatric symptoms (child >3 years)	Wilson disease	Ceruloplasmin, 24-hour urine copper, slit-lamp examination
Jaundice + splenomegaly + anemia + family history	Hereditary spherocytosis or other hemolytic anemia	CBC, reticulocytes, peripheral smear, osmotic fragility

Clinical Pearl: The “Triangular” Approach to Neonatal Cholestasis

When evaluating a neonate with conjugated hyperbilirubinemia, remember the “Big Three” that account for the majority of cases:

Biliary atresia (25-40%) — requires urgent surgical intervention
Idiopathic neonatal hepatitis (25-30%) — diagnosis of exclusion
Infectious, metabolic, and genetic causes (30-50% combined) — many are treatable

The key is to identify biliary atresia early (before 60 days) and to diagnose treatable metabolic conditions (galactosemia, tyrosinemia) before irreversible damage occurs.

6. Diagnostic Investigations

A stepwise, age-appropriate approach guided by clinical suspicion

Investigation of jaundice in pediatric patients should be guided by the age of the patient, type of hyperbilirubinemia, and clinical presentation. A systematic, stepwise approach ensures efficient diagnosis while avoiding unnecessary testing.

Initial Assessment: All Jaundiced Neonates

Investigation	Purpose	What to Look For	Practical Points
Total and direct (conjugated) bilirubin	Quantify jaundice severity; determine type	Total bilirubin level; direct greater than 1 mg/dL or greater than 20% = conjugated	Essential first step; cannot be replaced by transcutaneous measurement for direct fraction
Transcutaneous bilirubin (TcB)	Non-invasive screening for total bilirubin	Correlates with total serum bilirubin	Less reliable after phototherapy, in dark skin, at very high levels; confirm with serum if elevated
Blood type and Rh (mother and baby)	Identify ABO or Rh incompatibility	Type O mother with type A or B baby; Rh-negative mother with Rh-positive baby	May already be on record from prenatal care and delivery
Direct Coombs test (Direct Antiglobulin Test)	Detect antibody-coated red blood cells	Positive in immune hemolysis (Rh, ABO incompatibility)	May be weakly positive in ABO incompatibility; strongly positive in Rh disease
Complete blood count with reticulocyte count	Assess for anemia and hemolysis	Low hemoglobin = anemia; elevated reticulocytes = hemolysis or blood loss	Neonatal normal ranges differ from older children
Peripheral blood smear	Identify red cell morphology abnormalities	Spherocytes (spherocytosis, ABO), fragments (microangiopathy), target cells (thalassemia)	Request manual differential; automated may miss morphology changes

Using the Bhutani Nomogram (Hour-Specific Bilirubin)

Plot the total serum bilirubin against the infant’s age in hours on the Bhutani nomogram to determine risk zone:

High-risk zone (above 95th percentile): High likelihood of subsequent hyperbilirubinemia requiring treatment
High-intermediate zone (75th-95th percentile): Requires close monitoring
Low-intermediate zone (40th-75th percentile): Low risk, routine follow-up
Low-risk zone (below 40th percentile): Very low risk of significant hyperbilirubinemia

The nomogram guides decision-making for phototherapy threshold and timing of follow-up.

Additional Testing for Unconjugated Hyperbilirubinemia

If Hemolysis is Suspected

First-Line Tests

G6PD enzyme assay: Screen all male infants of at-risk ethnicity; may be falsely normal during acute hemolysis
End-tidal carbon monoxide (ETCOc): Elevated in hemolysis (bilirubin production); not widely available
Lactate dehydrogenase (LDH): Elevated in hemolysis
Haptoglobin: Decreased in hemolysis (less reliable in neonates)

Second-Line Tests

Hemoglobin electrophoresis: If thalassemia or sickle cell suspected
Osmotic fragility test: Hereditary spherocytosis (unreliable in neonates)
Eosin-5-maleimide (EMA) binding test: More reliable for spherocytosis
Pyruvate kinase assay: If pyruvate kinase deficiency suspected
Red cell enzyme panel: For unexplained hemolysis

If Prolonged Unconjugated Jaundice

Investigation	Purpose	When to Order
Thyroid function tests (TSH, free T4)	Exclude hypothyroidism	All prolonged jaundice; check newborn screening result first
Repeat fractionated bilirubin	Confirm still unconjugated; exclude developing conjugated component	All prolonged jaundice beyond 2 weeks
G6PD assay	Exclude G6PD deficiency as cause	Males of at-risk ethnicity; unexplained prolonged jaundice
Urine for reducing substances	Screen for galactosemia	If feeding issues, failure to thrive, hepatomegaly
UGT1A1 genetic testing	Confirm Gilbert or Crigler-Najjar syndrome	If persistent unexplained unconjugated hyperbilirubinemia

Investigation of Conjugated Hyperbilirubinemia (Neonatal Cholestasis)

Urgent Evaluation Required

Conjugated hyperbilirubinemia in a neonate or infant is a medical urgency. The priority is to identify biliary atresia (best outcomes with surgery before 60 days) and treatable metabolic conditions (galactosemia, tyrosinemia).

Baseline Cholestasis Workup

Investigation	Purpose	What to Look For	Clinical Significance
Liver function tests (ALT, AST, ALP, GGT, albumin)	Assess hepatocellular injury and synthetic function	ALT/AST elevation = hepatocellular injury; elevated ALP/GGT = cholestasis; low albumin = poor synthetic function	Very high transaminases (>1000) suggest viral hepatitis or ischemia; low GGT cholestasis suggests PFIC or bile acid synthesis defect
Coagulation studies (PT/INR, PTT)	Assess synthetic function and vitamin K status	Prolonged PT/INR may indicate liver failure or vitamin K deficiency	Give vitamin K and recheck; if still prolonged, indicates liver synthetic failure
Glucose	Screen for metabolic disease and liver failure	Hypoglycemia suggests metabolic disease or liver failure	Galactosemia, tyrosinemia, and liver failure all cause hypoglycemia
Ammonia	Screen for urea cycle defects and liver failure	Elevated ammonia indicates metabolic disease or severe liver failure	Must be processed immediately (on ice); false elevation if delayed
Abdominal ultrasound	Evaluate liver, gallbladder, and biliary system	Gallbladder presence/absence, choledochal cyst, liver size/echogenicity	Absent gallbladder or “triangular cord sign” suggests biliary atresia; fasting for 4 hours improves gallbladder visualization

Targeted Investigations by Suspected Etiology

If Biliary Atresia is Suspected

First-Line

Fasting abdominal ultrasound: Absent or small gallbladder, triangular cord sign, abnormal hepatic artery diameter
Hepatobiliary iminodiacetic acid (HIDA) scan: No excretion into intestine after 24 hours suggests obstruction (must pretreat with phenobarbital for 5 days to be reliable)

Definitive

Intraoperative cholangiogram: Gold standard for diagnosis
Liver biopsy: Shows bile duct proliferation, portal fibrosis, bile plugs
ERCP or MRCP: May visualize biliary anatomy but less useful in neonates

If Metabolic Disease is Suspected

Condition	First-Line Test	Confirmatory Test	Urgent Action
Galactosemia	Urine reducing substances (positive); newborn screen (if performed)	Galactose-1-phosphate uridyltransferase (GALT) enzyme assay	Stop all lactose/galactose immediately while awaiting results
Tyrosinemia type I	Urine succinylacetone (highly specific); elevated alpha-fetoprotein	Fumarylacetoacetate hydrolase (FAH) enzyme assay; genetic testing	Start nitisinone (NTBC) if confirmed; dietary tyrosine/phenylalanine restriction
Alpha-1 antitrypsin deficiency	Alpha-1 antitrypsin level (may be falsely normal as acute phase reactant)	Alpha-1 antitrypsin phenotype (Pi typing); genetic testing	Supportive care; monitor for progression
Cystic fibrosis	Immunoreactive trypsinogen (newborn screen); sweat chloride test	CFTR genetic testing	Pancreatic enzyme replacement; pulmonary care
Bile acid synthesis defects	Urine bile acid analysis by mass spectrometry	Genetic testing for specific enzyme defects	Primary bile acid supplementation may be curative
Niemann-Pick type C	Filipin staining of cultured fibroblasts	NPC1/NPC2 genetic testing	Supportive care; miglustat may slow progression

If Infection is Suspected

Bacterial Infection

Blood culture: Essential in all ill-appearing jaundiced neonates
Urine culture: Urinary tract infection can present with jaundice
Lumbar puncture: If sepsis or meningitis suspected
Complete blood count: Leukocytosis, left shift, thrombocytopenia
C-reactive protein, procalcitonin: Markers of bacterial infection

TORCH Infections

CMV urine PCR: Most sensitive for congenital CMV (first 3 weeks)
Toxoplasma IgM and IgG: With avidity testing
Rubella IgM: Congenital rubella syndrome
HSV PCR (blood, CSF): If disseminated herpes suspected
Syphilis serology: RPR/VDRL, confirmatory testing
Parvovirus B19 serology/PCR: Hydrops, anemia

If Genetic/Syndromic Cause is Suspected

Condition	Supporting Investigations	Confirmatory Test
Alagille syndrome	Echocardiogram (pulmonary stenosis), spine X-ray (butterfly vertebrae), ophthalmology (posterior embryotoxon)	JAG1 or NOTCH2 genetic testing
Progressive familial intrahepatic cholestasis (PFIC)	GGT level (low in PFIC1 and PFIC2, elevated in PFIC3); bile acid levels	Genetic testing (ATP8B1, ABCB11, ABCB4)
Neonatal hemochromatosis	Ferritin (very high), transferrin saturation; MRI showing iron deposition in liver and pancreas (sparing spleen)	Lip biopsy showing salivary gland siderosis; clinical diagnosis

Investigation of Jaundice Beyond Infancy

Investigation	Purpose	Key Findings
Liver function tests	Assess hepatocellular injury and cholestasis	Pattern helps distinguish hepatocellular (high ALT/AST) from cholestatic (high ALP/GGT)
Viral hepatitis serologies	Diagnose hepatitis A, B, C	Hepatitis A IgM (acute HAV), HBsAg and anti-HBc IgM (acute HBV), HCV antibody and RNA
EBV and CMV serologies	Diagnose viral hepatitis	EBV VCA IgM (acute EBV), CMV IgM
Autoimmune markers	Diagnose autoimmune hepatitis	ANA, anti-smooth muscle antibody (ASMA), anti-LKM-1, elevated IgG
Ceruloplasmin	Screen for Wilson disease	Low ceruloplasmin (less than 20 mg/dL) suggests Wilson disease; may be normal in 5-15%
24-hour urine copper	Diagnose Wilson disease	Elevated (>100 mcg/24h in symptomatic, >40 mcg/24h suspicious)
Slit-lamp examination	Detect Kayser-Fleischer rings	Present in most neurological Wilson disease; may be absent in hepatic presentation
Hemolysis workup	Diagnose hemolytic causes of unconjugated jaundice	CBC, reticulocytes, LDH, haptoglobin, peripheral smear, Coombs test
Abdominal ultrasound	Evaluate liver, biliary system, spleen	Hepatomegaly, gallstones, dilated bile ducts, splenomegaly

Liver Biopsy: When and Why

Indications for Liver Biopsy in Pediatric Jaundice

Neonatal cholestasis: To differentiate biliary atresia from neonatal hepatitis when non-invasive tests are inconclusive
Suspected autoimmune hepatitis: To confirm diagnosis and assess disease severity
Wilson disease: Hepatic copper quantification if diagnosis unclear
Unexplained chronic liver disease: When diagnosis cannot be established by other means
Assessment of fibrosis/cirrhosis: To guide prognosis and management

Considerations in children: Usually requires sedation or general anesthesia; ensure adequate coagulation (INR less than 1.5, platelets greater than 50,000) before procedure.

Phototherapy Monitoring

During phototherapy for unconjugated hyperbilirubinemia, the following monitoring is recommended:

Parameter	Frequency	Purpose
Total serum bilirubin	Every 4-24 hours depending on level and rate of rise	Assess response to therapy; determine when to discontinue
Temperature	Every 3-4 hours	Monitor for hyperthermia from phototherapy lights
Hydration status	Each nursing assessment	Phototherapy increases insensible water loss
Skin assessment	Each nursing assessment	Monitor for rashes, “bronze baby syndrome” (in cholestasis)
Eye protection	Continuous	Ensure eye shields remain in place to prevent retinal damage

Investigation Algorithm Summary

Stepwise Approach to Pediatric Jaundice Investigation:

Step 1: Obtain total and direct bilirubin — determine type of hyperbilirubinemia
Step 2: If unconjugated predominant → blood type, Coombs, CBC, reticulocytes, smear
Step 3: If conjugated (direct greater than 1 mg/dL or greater than 20%) → URGENT evaluation: liver function tests, coagulation, glucose, ultrasound
Step 4: For neonatal cholestasis → HIDA scan (after phenobarbital), metabolic screen, TORCH serologies, alpha-1 antitrypsin
Step 5: If biliary atresia suspected → surgical consultation for intraoperative cholangiogram ± liver biopsy
Step 6: For older children → viral hepatitis serologies, autoimmune markers, Wilson disease screen
Step 7: If diagnosis remains unclear → consider liver biopsy, genetic testing, referral to pediatric hepatology

Clinical Pearl: The Newborn Screen

Always check the newborn screening results when evaluating a jaundiced infant. Many causes of jaundice are included on newborn screening panels:

Congenital hypothyroidism: Elevated TSH on newborn screen
Galactosemia: Elevated galactose or reduced GALT activity
Cystic fibrosis: Elevated immunoreactive trypsinogen (IRT)
Tyrosinemia: Elevated succinylacetone (on some panels)
G6PD deficiency: Included on some state panels

However, a normal newborn screen does not completely exclude these conditions — clinical suspicion should prompt confirmatory testing.

7. Clinical Decision-Making

Practical algorithms and decision pathways for pediatric jaundice

Clinical decision-making in pediatric jaundice requires rapid assessment of urgency, systematic evaluation based on the type of hyperbilirubinemia, and timely intervention to prevent complications. This section provides practical frameworks for managing jaundiced pediatric patients in various clinical scenarios.

Step 1: Is This Urgent?

Clinical Scenario	Urgency Level	Immediate Action
Signs of acute bilirubin encephalopathy (lethargy, hypotonia, high-pitched cry, opisthotonus, seizures)	EMERGENT	Immediate exchange transfusion preparation; intensive phototherapy while arranging; NICU admission
Total bilirubin at or above exchange transfusion threshold	EMERGENT	Intensive phototherapy; prepare for exchange transfusion; type and crossmatch; call NICU
Jaundice in first 24 hours of life	EMERGENT	Immediate total and direct bilirubin, blood type, Coombs, CBC; start phototherapy if indicated; evaluate for sepsis
Rapidly rising bilirubin (greater than 0.2 mg/dL/hour or greater than 5 mg/dL/day)	EMERGENT	Intensive phototherapy; evaluate for hemolysis; consider IVIG if immune-mediated; monitor closely
Conjugated hyperbilirubinemia with pale stools (any age)	URGENT	Same-day ultrasound; urgent referral to pediatric gastroenterology/hepatology; expedite biliary atresia workup
Jaundice with fever, ill appearance, or poor feeding	URGENT	Septic workup; empiric antibiotics if sepsis suspected; evaluate for metabolic disease
Total bilirubin approaching phototherapy threshold	URGENT	Start phototherapy; identify cause; close monitoring with repeat bilirubin in 4-6 hours
Prolonged jaundice beyond 2 weeks (term) or 3 weeks (preterm)	URGENT	Fractionated bilirubin within 24-48 hours; if conjugated elevated, urgent cholestasis workup
Physiological jaundice, well-appearing infant	ROUTINE	Plot bilirubin on hour-specific nomogram; determine follow-up based on risk zone; ensure adequate feeding
Breast milk jaundice, thriving infant	ROUTINE	Confirm unconjugated hyperbilirubinemia; reassure parents; continue breastfeeding; routine follow-up

Step 2: Determine Type of Hyperbilirubinemia

Unconjugated Predominant

Definition: Direct bilirubin less than 1 mg/dL (if total less than 5) OR less than 20% of total

Proceed to: Algorithm A (Neonatal) or Algorithm C (Older child)

Key concern: Risk of kernicterus at very high levels

Conjugated Predominant

Definition: Direct bilirubin greater than 1 mg/dL (if total less than 5) OR greater than 20% of total

Proceed to: Algorithm B (Cholestasis workup)

Key concern: Biliary atresia — time-sensitive diagnosis

Step 3: Follow the Appropriate Algorithm

Algorithm A: Neonatal Unconjugated Hyperbilirubinemia

Clinical Scenario	Most Likely Diagnosis	Action
Jaundice in first 24 hours + positive Coombs + anemia	Hemolytic disease of newborn (Rh or ABO)	Intensive phototherapy; consider IVIG (0.5-1 g/kg); monitor for exchange threshold; check serial bilirubin and hemoglobin
Jaundice in first 24 hours + negative Coombs + anemia	G6PD deficiency, red cell membrane defect, or non-immune hemolysis	Phototherapy; G6PD assay; peripheral smear; avoid oxidant stressors; monitor closely
Jaundice days 2-5 + well-appearing + feeding well + normal stools	Physiological jaundice or breastfeeding jaundice	Plot on Bhutani nomogram; phototherapy if above threshold; ensure adequate feeding; schedule follow-up based on risk zone
Jaundice days 2-5 + weight loss greater than 7% + decreased stools	Breastfeeding jaundice (inadequate intake)	Lactation support; increase feeding frequency; consider supplementation; phototherapy if indicated; monitor weight
Jaundice + visible cephalohematoma or extensive bruising	Increased bilirubin load from sequestered blood	Phototherapy if indicated; anticipate higher peak bilirubin; monitor hemoglobin
Prolonged jaundice beyond 2 weeks + well + normal stools + exclusively breastfed	Breast milk jaundice (if unconjugated confirmed)	Confirm direct bilirubin is normal; reassure; continue breastfeeding; recheck if not improving by 3-4 weeks
Prolonged jaundice + constipation + hypotonia + large fontanelle	Congenital hypothyroidism	Check thyroid function (TSH, free T4); confirm newborn screen result; start levothyroxine if confirmed

Algorithm B: Neonatal/Infant Conjugated Hyperbilirubinemia (Cholestasis)

Time-Critical: Biliary Atresia Workup

The Kasai portoenterostomy has the best outcomes when performed before 60 days of age. Do not delay evaluation.

Clinical Scenario	Most Likely Diagnosis	Action
Conjugated hyperbilirubinemia + acholic stools + hepatomegaly	Biliary atresia (until proven otherwise)	URGENT: Fasting ultrasound, HIDA scan (after phenobarbital pretreatment), surgical consultation for cholangiogram
Conjugated hyperbilirubinemia + cystic structure on ultrasound	Choledochal cyst	Surgical consultation; MRCP if needed for anatomy; plan surgical excision
Conjugated hyperbilirubinemia + vomiting + hepatomegaly + E. coli sepsis	Galactosemia	STOP all lactose/galactose IMMEDIATELY; GALT enzyme assay; supportive care
Conjugated hyperbilirubinemia + coagulopathy + elevated AFP + cabbage odor	Tyrosinemia type I	Urine succinylacetone; start nitisinone if confirmed; dietary restriction
Conjugated hyperbilirubinemia + characteristic facies + heart murmur	Alagille syndrome	Echocardiogram, spine X-ray, ophthalmology exam; JAG1/NOTCH2 genetic testing
Conjugated hyperbilirubinemia + hepatosplenomegaly + petechiae + microcephaly	Congenital infection (TORCH)	TORCH serologies, urine CMV PCR; treat specific infection if identified
Conjugated hyperbilirubinemia + normal ultrasound + variable stools	Idiopathic neonatal hepatitis or other cause	Complete cholestasis workup; liver biopsy if diagnosis unclear; supportive care

Algorithm C: Childhood Jaundice (Beyond Infancy)

Clinical Scenario	Most Likely Diagnosis	Action
Acute jaundice + fever + malaise + elevated transaminases	Viral hepatitis (A, B, EBV, CMV)	Viral serologies; supportive care; monitor liver function; assess for acute liver failure
Jaundice + anemia + splenomegaly + family history	Hemolytic anemia (hereditary spherocytosis, thalassemia)	CBC, reticulocytes, peripheral smear, Coombs; hemoglobin electrophoresis; EMA binding or osmotic fragility
Adolescent + intermittent mild jaundice + worse with fasting/illness	Gilbert syndrome	Confirm unconjugated hyperbilirubinemia with normal liver function tests; reassure; no treatment needed
Child greater than 3 years + jaundice + neuropsychiatric symptoms	Wilson disease	Ceruloplasmin, 24-hour urine copper, slit-lamp exam; liver biopsy for copper quantification if needed
Jaundice + fatigue + elevated transaminases + autoantibodies	Autoimmune hepatitis	ANA, ASMA, anti-LKM-1, IgG level; liver biopsy; start immunosuppression if confirmed
Jaundice + abdominal pain + elevated ALP/GGT + inflammatory bowel disease	Primary sclerosing cholangitis	MRCP to assess bile ducts; liver biopsy; monitor for complications

Phototherapy Decision-Making

Using AAP Phototherapy Guidelines (Term and Late Preterm Infants ≥35 weeks)

The AAP provides hour-specific thresholds for initiating phototherapy based on gestational age and risk factors:

Higher risk: Isoimmune hemolytic disease, G6PD deficiency, asphyxia, significant lethargy, temperature instability, sepsis, acidosis, or albumin less than 3.0 g/dL
Medium risk: Gestational age 35-37 6/7 weeks with no other risk factors, or ≥38 weeks with risk factors
Lower risk: Gestational age ≥38 weeks and well

Use the AAP phototherapy nomogram (available online and in AAP guidelines) to determine if phototherapy is indicated based on total serum bilirubin, age in hours, and risk category.

Phototherapy Thresholds (Approximate Values for Reference)

Age	Lower Risk (≥38 weeks, well)	Medium Risk	Higher Risk
24 hours	~12 mg/dL	~10 mg/dL	~8 mg/dL
48 hours	~15 mg/dL	~13 mg/dL	~11 mg/dL
72 hours	~18 mg/dL	~15 mg/dL	~13 mg/dL
96+ hours	~20 mg/dL	~17 mg/dL	~15 mg/dL

Note: These are approximate values for illustration. Always use the official AAP nomograms for clinical decision-making. Preterm infants less than 35 weeks have lower thresholds.

“What Do I Do If…” Decision Reference

Clinical Situation	Immediate Action	Next Step
Bilirubin is rising despite phototherapy	Ensure phototherapy is optimized (intensive phototherapy, check irradiance, maximize skin exposure)	Recheck bilirubin in 4-6 hours; consider IVIG if hemolytic; prepare for exchange if approaching threshold
Parents refuse phototherapy	Explain risks of kernicterus clearly and compassionately; document discussion; involve social work if needed	Offer home phototherapy if available and appropriate; arrange close outpatient follow-up if parents still refuse
Bilirubin rebounds after stopping phototherapy	Restart phototherapy if above threshold; look for ongoing hemolysis	Investigate cause (G6PD, ongoing hemolysis); extend phototherapy duration before next attempt to stop
Infant is being discharged early (less than 48 hours)	Measure bilirubin before discharge; plot on Bhutani nomogram; assess risk factors	Schedule follow-up within 24-48 hours based on risk zone; provide jaundice education to parents
Cannot obtain serum bilirubin promptly	Use transcutaneous bilirubin for screening; if elevated or infant has risk factors, send serum urgently	Do not rely solely on TcB after phototherapy or if TcB is high; serum confirmation required
Prolonged jaundice and parents report normal stool color	Verify stool color with stool color card; obtain fractionated bilirubin	If direct bilirubin elevated despite reported normal stools, proceed with cholestasis workup
Suspected biliary atresia but HIDA shows excretion	HIDA excretion significantly decreases but does not exclude biliary atresia	If clinical suspicion remains high, proceed to surgical consultation and intraoperative cholangiogram
Well infant with isolated elevated direct bilirubin	Repeat to confirm; if persistent, begin cholestasis workup	Conjugated hyperbilirubinemia is always pathological — do not attribute to physiological jaundice

Exchange Transfusion Considerations

Indications for Exchange Transfusion

Exchange transfusion is indicated when:

Total serum bilirubin exceeds exchange threshold on AAP nomogram (typically 20-25 mg/dL depending on age and risk factors)
Signs of acute bilirubin encephalopathy are present regardless of bilirubin level
Bilirubin continues to rise despite intensive phototherapy
Bilirubin is within 2-3 mg/dL of exchange threshold and rising rapidly

Preparation: Type and crossmatch; obtain vascular access; correct any coagulopathy; have calcium gluconate available; ensure NICU setting with monitoring capabilities.

Troubleshooting Persistent or Refractory Jaundice

Ask These Questions

Is the diagnosis correct? — Reconfirm the type of hyperbilirubinemia (repeat fractionated bilirubin)
Is there ongoing hemolysis? — Check hemoglobin trend, reticulocyte count, and look for new triggers
Is phototherapy being delivered effectively? — Check irradiance, skin exposure, and distance from light source
Are there multiple contributing factors? — Hemolysis + dehydration + bruising can all contribute
Is there an underlying metabolic or genetic condition? — Consider expanded workup if not responding as expected
Was the direct bilirubin checked? — An evolving conjugated component may indicate developing cholestasis
Is the infant feeding adequately? — Poor intake increases enterohepatic circulation

Follow-Up Recommendations

Scenario	Follow-Up Timing	What to Assess
Discharged before 24 hours of age	Within 24 hours	Bilirubin level, weight, feeding adequacy
Discharged at 24-48 hours, low-risk zone	Within 48 hours (by day 4-5)	Bilirubin if clinically jaundiced, weight, feeding
Discharged at 24-48 hours, low-intermediate zone	Within 24-48 hours	Bilirubin level, weight, feeding
Discharged at 24-48 hours, high-intermediate or high-risk zone	Within 24 hours	Bilirubin level (must be measured), weight, feeding
After stopping phototherapy	Recheck bilirubin in 12-24 hours; follow-up in 24-48 hours	Rebound hyperbilirubinemia, ongoing hemolysis
Prolonged jaundice (breast milk jaundice confirmed)	Weekly until resolving	Continued resolution, normal stools, weight gain
After Kasai procedure for biliary atresia	Close follow-up with pediatric hepatology	Bile flow, bilirubin trend, liver function, growth, complications

8. Clinical Pearls and Pitfalls

Practical wisdom — learn from successes and avoid common mistakes

Must-Know Clinical Pearls

Jaundice in the first 24 hours is NEVER physiological: Always investigate immediately for hemolytic disease, sepsis, or other pathological causes. This is a critical teaching point that can be life-saving.

Conjugated hyperbilirubinemia is ALWAYS pathological: Unlike unconjugated hyperbilirubinemia, there is no physiological cause for conjugated hyperbilirubinemia at any age. Always investigate promptly.

Pale stools are a surgical emergency until proven otherwise: Acholic (clay-colored) stools in a jaundiced infant should trigger urgent evaluation for biliary atresia. The Kasai procedure outcomes are time-dependent.

The “60-day rule” for biliary atresia: The Kasai portoenterostomy has approximately 70% success when performed before 60 days of age, but this drops to less than 25% after 90 days. Early referral is critical.

Breast milk jaundice is a diagnosis of exclusion: Before attributing prolonged jaundice to breast milk, you must confirm the hyperbilirubinemia is unconjugated and rule out other causes including biliary atresia.

The stool color card saves lives: Providing parents with a stool color card and educating them about the significance of pale stools enables earlier detection of biliary atresia.

G6PD deficiency can cause both acute hemolysis and chronic hyperbilirubinemia: Consider G6PD in any neonate with unexplained jaundice, especially those of Mediterranean, African, Middle Eastern, or Asian descent.

Check the newborn screening results: Many causes of jaundice (hypothyroidism, galactosemia, cystic fibrosis) are included on newborn screening. Always verify results are available and normal.

Galactosemia is a medical emergency: If galactosemia is suspected (jaundice, vomiting, hepatomegaly, cataracts, E. coli sepsis), stop all lactose immediately while awaiting confirmatory testing.

Wilson disease presents after age 3: Copper accumulates over years, so Wilson disease does not present in infancy. Consider it in any child over 3 years with unexplained liver disease, especially with neuropsychiatric symptoms.

Critical Pitfalls to Avoid

Attributing prolonged jaundice to breast milk without checking direct bilirubin: This is a dangerous assumption. Always obtain a fractionated bilirubin to rule out conjugated hyperbilirubinemia before diagnosing breast milk jaundice.

Relying solely on visual assessment of jaundice: Visual inspection is unreliable, especially in dark-skinned infants or under artificial lighting. Always measure bilirubin when jaundice is present or suspected.

Delaying cholestasis workup in a jaundiced infant with pale stools: Every day of delay in diagnosing biliary atresia worsens outcomes. Initiate urgent evaluation immediately — do not wait and watch.

Using ceftriaxone in a jaundiced neonate: Ceftriaxone displaces bilirubin from albumin, increasing the risk of kernicterus. It is contraindicated in jaundiced neonates and should be avoided in the first 28 days of life.

Stopping breastfeeding for breast milk jaundice: Breast milk jaundice is benign and does not require cessation of breastfeeding. Temporary interruption may be considered for diagnostic purposes in severe cases, but breastfeeding should be strongly encouraged to continue.

Assuming a normal gallbladder on ultrasound excludes biliary atresia: While an absent or contracted gallbladder is suggestive, some infants with biliary atresia have a visible gallbladder. Clinical suspicion should drive further evaluation.

Ignoring subtle signs of bilirubin encephalopathy: Early signs (lethargy, poor feeding, hypotonia) are nonspecific and easily missed. A high index of suspicion and low threshold for intensive treatment can prevent progression to kernicterus.

Not repeating bilirubin after phototherapy: Bilirubin can rebound after stopping phototherapy. Always recheck within 12-24 hours, especially if there is ongoing hemolysis or the level was high.

Accepting parental report of normal stool color without verification: Parents may not recognize subtle changes in stool color. Use a stool color card and ask to see the stool directly when possible.

Failing to consider multiple contributing causes: Jaundice often results from more than one factor (e.g., ABO incompatibility + breastfeeding jaundice + cephalohematoma). Address all contributing factors for optimal management.

Key Takeaways

Always fractionate the bilirubin — distinguishing unconjugated from conjugated hyperbilirubinemia fundamentally changes the differential diagnosis and urgency of evaluation.
Timing matters — jaundice in the first 24 hours is always pathological; prolonged jaundice beyond 2 weeks requires investigation; biliary atresia outcomes depend on early surgical intervention.
Conjugated hyperbilirubinemia equals urgent evaluation — there is no benign cause of conjugated hyperbilirubinemia; always investigate promptly with biliary atresia at the top of the differential.
Stool color is a vital sign in neonatal jaundice — pale or acholic stools indicate biliary obstruction and require immediate action.
Use hour-specific nomograms — the Bhutani nomogram helps stratify risk and guides decisions about phototherapy and follow-up in term and late preterm infants.
Phototherapy is highly effective but must be optimized — ensure adequate irradiance, maximize skin exposure, and maintain hydration for best results.
Exchange transfusion saves lives — do not delay when bilirubin approaches exchange threshold or when signs of encephalopathy are present.
Breast milk jaundice is benign but requires exclusion of pathological causes — always confirm the hyperbilirubinemia is unconjugated before making this diagnosis.
Think metabolically — galactosemia, tyrosinemia, and other metabolic disorders may present with jaundice and are treatable if diagnosed early.
Kernicterus is preventable — with appropriate screening, monitoring, and treatment, bilirubin-induced neurological dysfunction should never occur.

Quick Reference Algorithm

Systematic Approach to Pediatric Jaundice:

Assess urgency: Is this an emergency? (First 24 hours, signs of encephalopathy, very high bilirubin, acholic stools)
Measure bilirubin: Obtain total and direct (fractionated) bilirubin in all cases requiring evaluation
Determine type: Unconjugated (direct less than 20%) versus conjugated (direct greater than 20% or greater than 1 mg/dL)
For unconjugated: Plot on Bhutani nomogram (neonates); evaluate for hemolysis (blood type, Coombs, CBC); treat with phototherapy if indicated
For conjugated: Urgent cholestasis workup; ultrasound, liver function tests; exclude biliary atresia as priority
Identify etiology: Use history, examination, and targeted investigations to determine the cause
Treat appropriately: Phototherapy for unconjugated; specific treatment for underlying cause; surgical referral for biliary obstruction
Monitor and follow up: Recheck bilirubin after phototherapy; ensure appropriate follow-up based on risk; provide parent education

Parent Education Points

What to Tell Parents

Jaundice is common in newborns and usually harmless, but it needs monitoring
Adequate feeding (8-12 times per day) helps eliminate bilirubin
Watch for signs of worsening: increasing yellow color, poor feeding, excessive sleepiness
Stool color matters: pale or white stools need immediate medical attention
Keep all follow-up appointments for bilirubin checks

When to Seek Immediate Care

Baby is difficult to wake or very sleepy
Baby is not feeding well or feeding less than usual
Baby has a high-pitched cry or is very irritable
Baby’s body is stiff or arching
Jaundice is spreading to legs and feet
Stools are pale, clay-colored, or white
Baby has fever or seems unwell